| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.1 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.099 | 0.1 |